Aphea.Bio
Develops microbial-based biostimulant and biocontrol products using a high-throughput platform to protect crops while reducing chemical inputs.
- dt and ls
- biotechnology
- sustainable development goals
- woman founder
- climate tech
- spinout
- b corp
- nif defense security and resilience
- climate adaptation
- synthetic biology
- regenerative agriculture
- crop protection
- fertilizer
- nif health crisis preparedness
- primary production
- microbiology
- biotechnology in food
- nif food security
- fertigation
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 -12.5x EV/EBITDA | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | €1.9m | Grant | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Aphea.Bio is a biotechnology startup that operates in the agricultural sector. The company focuses on the discovery and development of novel and unique strains of biologicals, with a proprietary collection of over 15,000 strains. These biologicals are used to create biocontrol and biostimulant products that help farmers maintain the health of their crops.
The company's business model is based on the use of advanced technologies such as microbiome mapping and high-throughput analytical methods to identify beneficial plant-microbe interactions. These technologies allow Aphea.Bio to screen thousands of potential product candidates quickly and efficiently.
Once potential candidates are identified, the company uses in-house data mining capabilities and expertise to evaluate these leads. This process involves high-throughput, automated plant phenotyping and AI-based disease scoring algorithms. The goal is to identify the candidates that will make a significant difference for the plants and, ultimately, the farmers.
The company also has an experienced team of field trial managers and scientific experts who implement extensive field trial programs. These programs, combined with the company's in-house data management and statistics system, allow Aphea.Bio to perform in-depth analysis of their data and steer their development process effectively.
In terms of revenue, Aphea.Bio likely makes money by selling their biocontrol and biostimulant products to farmers and agricultural businesses. The company's unique approach and proprietary strains give it a competitive edge in the market, potentially allowing it to charge premium prices for its products.
Keywords: Biotechnology, Agriculture, Biocontrol, Biostimulant, Microbiome Mapping, High-Throughput Analytical Methods, Data Mining, Plant Phenotyping, AI-Based Disease Scoring, Field Trial Programs.